MOTS-c: mitochondrial peptide, mostly rodent evidence

Key takeaways

• MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial 12S rRNA gene. Lee 2015 in Cell Metabolism characterized it as a peptide that improves metabolic homeostasis and reduces obesity and insulin resistance in mice .
• The metabolic effect runs through AMPK. In rodent and cell models MOTS-c blocks the folate cycle and de novo purine synthesis, which builds up AICAR and activates AMPK, increasing glucose uptake in skeletal muscle . The AMPK-dependence held up in later mitochondrial-derived-peptide work .
• Circulating MOTS-c is measurable in human plasma and rises with exercise, about 12-fold in skeletal muscle and 1.6-fold in blood in one human cohort . No human study of administered MOTS-c has reported pharmacokinetics, pharmacodynamics, or outcomes; the first registered trial, a Phase 2a in prediabetes, is recruiting .
• MOTS-c is not FDA-approved and is banned in sport. WADA prohibits it at all times as an AMPK activator (S4.4 metabolic modulators), with no therapeutic-use exemption available . It is not authorized for pharmacy compounding either: the FDA flagged this peptide class for significant safety risks and referred MOTS-c to a July 2026 advisory-committee review of the 503A list .
• Framing MOTS-c as a settled mitochondrial-longevity or exercise-mimetic therapy runs ahead of the data. The rodent metabolic work is the strongest part of the literature; the human outcome claims are unverified.

What MOTS-c is and where it comes from

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. The peptide comes from a short open reading frame embedded in the 12S ribosomal RNA gene of the mitochondrial genome. That location is unusual. Almost every peptide in human physiology is encoded by the nuclear genome and imported into mitochondria as needed; only a handful, MOTS-c and humanin among them, are encoded inside the mitochondrial genome itself. These are called mitochondrial-derived peptides, or MDPs, and more have been identified since humanin was first described .

The mature peptide is 16 amino acids long. It is thought to be translated by cytoplasmic ribosomes acting on mitochondrial transcripts that escape the organelle, not by the mitochondrial machinery that makes the 13 canonical oxidative-phosphorylation subunits. Once secreted into the circulation, it can act both inside the mitochondrion and at distant tissues such as skeletal muscle and adipose tissue .

Lee 2015: the foundational rodent metabolic program

Changhan Lee, Jennifer Zeng, Brian Drew, and colleagues published "The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance" in Cell Metabolism in 2015 (PMID 25738459). The work combined cell-culture myocyte experiments with mouse studies .

The mouse findings: MOTS-c given by intraperitoneal injection improved insulin sensitivity in diet-induced obese mice, reduced age-related insulin resistance in older mice, and increased glucose uptake in skeletal muscle. The proposed mechanism was AMPK activation, driven by MOTS-c blocking the folate cycle and de novo purine biosynthesis so that AICAR accumulates. All of this is mouse and cell data .

What the human literature actually says

Human MOTS-c data comes in two forms. The first is observational: measuring circulating MOTS-c in blood samples. MOTS-c is detectable in human plasma (Lee 2015 first reported it in human samples) , and it rises with exercise. In one study, a bout of exercise raised MOTS-c roughly 12-fold in skeletal muscle and about 1.6-fold in the circulation of human subjects . That supports a working circulating MDP system in people. It says nothing about what an injected dose would do.

The second form is interventional, and here the data is thin. The pharmacokinetic and pharmacodynamic work on administered MOTS-c is in rodents: Lee gave it to mice by injection , and Reynolds treated aged mice with intermittent MOTS-c and measured improved running capacity and healthspan . No human pharmacokinetic or pharmacodynamic study of administered MOTS-c has been published, and there is no randomized placebo-controlled human outcome trial in obesity, insulin resistance, sarcopenia, or longevity endpoints. The first registered human protocol, a Phase 2a randomized placebo-controlled trial of MOTS-c for insulin sensitivity in adults with prediabetes and overweight or obesity (NCT07505745, sponsored by Hudson Biotech), is recruiting and has not read out .

• Yes: circulating MOTS-c is measurable in human plasma and climbs with acute exercise .
• Yes: the rodent metabolic program reproduces across labs .
• No: there is no FDA-approved MOTS-c product .
• No: there is no published randomized human outcome trial of administered MOTS-c.
• No: rodent dose ranges and schedules do not transfer to human protocols without dedicated PK work.

AMPK and the exercise-mimetic claim

MOTS-c gets called an exercise mimetic because AMPK activation is one of the things contracting muscle does, and exogenous MOTS-c activates AMPK in rodent muscle . Exercise itself raises endogenous MOTS-c in humans . The mechanistic link is fair. The leap from there to injecting MOTS-c replacing structured exercise is something the human evidence does not support.

Exercise sets off a coordinated response across many pathways at once: AMPK activation, PGC-1-alpha-driven mitochondrial biogenesis, capillary growth, satellite-cell proliferation, mechanotransduction, and cardiovascular adaptation. Hitting one node of that with a single peptide is not the same as driving the whole system. MOTS-c is a candidate metabolic signaling peptide with rodent evidence for AMPK activation. Calling it a stand-in for training is a claim the published human data has not earned.

Longevity framing and the broader MDP family

The wider MDP family includes humanin, which has the longest track record in neuroprotection and cytoprotection, plus MOTS-c and several more peptides identified since . A few family members show up in human genetics: a humanin coding variant tracks with lower humanin levels and more cognitive decline in one African-American cohort, and a MOTS-c variant tracks with higher type 2 diabetes prevalence in Japanese men . The case for MOTS-c as a longevity intervention usually leans on this family-level pattern plus the Lee 2015 rodent metabolic data.

A genetic association in a cohort is not a dosing protocol. The published human MDP work is still descriptive: it maps where these peptides sit in mitochondrial signaling biology, and it makes MOTS-c the best-characterized member in metabolic contexts. It does not establish a human therapeutic regimen. Any honest write-up of MOTS-c stays on mechanism and rodent evidence and stops short of a recommended human dose.

Not approved, banned in sport, and under FDA compounding review

There is no FDA-approved MOTS-c drug and no approved human use . Athletes should know it is banned outright. WADA lists MOTS-c as prohibited at all times under S4.4 metabolic modulators, in the AMPK-activator subsection, and no therapeutic-use exemption is available because there is no approved medical use .

Pharmacy compounding is not a clean route either. The FDA placed peptides like MOTS-c in the group of bulk drug substances it says may present significant safety risks in compounding . In April 2026 the FDA reopened the question for seven of these peptides, MOTS-c among them, and referred them to its Pharmacy Compounding Advisory Committee; the committee is scheduled to review MOTS-c on July 23, 2026 as part of deciding whether these substances belong on the Section 503A compounding list . Until that plays out, a MOTS-c vial sold for research is not the regulatory equivalent of an approved drug.

Editorial summary

MOTS-c is the best-characterized mitochondrial-derived peptide, and the Lee 2015 Cell Metabolism program is the strongest evidence it has. The rodent metabolic-homeostasis results reproduce, the AMPK mechanism is biologically reasonable, and the family clearly plays a role in mitochondrial signaling. What is missing is human outcome data. A Phase 2a trial is finally recruiting; until it reads out, the honest read on MOTS-c is strong mechanism, unproven benefit in people.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these pieces: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 7 entries, all primary canon (PubMed, ClinicalTrials.gov, FDA, the Federal Register, and USADA), last reviewed 2026-07-08.

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.